https://www.fda.gov/news-events/press-announcements/fda-approves-new-buprenorphine-treatment-option-opioid-use-disorder
0
0
FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder - FDA.gov
+ 89 more
5/23/23 at 7:00pm
Organization
FDA.gov
Author
Office of the Commissioner
Details
30 words
Summarize
Sensitive Subjects Drug & Alcohol Treatment Drugs & Medications Business & Industrial FDA New Buprenorphine Treatment Option Brixadi
The U.S. Food and Drug Administration approved Brixadi to treat moderate to severe opioid use disorder (OUD).
Create an account or login to join the discussion